Posted by bleauberry on May 11, 2011, at 4:55:00
In reply to Dual AD Tx Same As Monotheraphy For MDD, posted by Phillipa on May 10, 2011, at 20:22:25
This study has a number of flaws and possible bias. The one thing that stood out in my mind was how they made a blanket statement concerning dual ADs, when the most appropriate potent dual AD combos were not even used. Not a single TCA in there. I think they put more credence in Wellbutrin than it deserves....it did not pass the test as an antidepressant in other countries. Why use such a lame AD? Remeron isn't exactly a powerhorse either. I'm not saying these meds don't work occasionally, they just don't have the track record or the umph of TCAs or other choices. And along the lines of dual ADs, how come they didn't use Milnacipran. It's a built in dual AD all in one. Except for a couple of the TCAs, it is the only one. Effexor gets the dual AD classification, but in reality is hardly so. When combined with Remeron, their is no evidence that it actually increases NE, contrary to the hype. This whole study looks flawed to me due to weak med choices, or cherry picked med choices.
What ever happened to good ole prozac? Ya know, a lot of ssris have jumped on the band wagon. But personally I have just not seen any perform as well as prozac from a subjective audience point of view. I mention prozac because it actually does have evidence that it increases all three of the major neurotransmitters, where lexapro is just one.
Anyway, I'm just rambling. Don't mind me.
poster:bleauberry
thread:985044
URL: http://www.dr-bob.org/babble/20110502/msgs/985064.html